echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Xianju Pharmaceutical Ropivacaine Hydrochloride Injection Passed Consistency Evaluation

    Xianju Pharmaceutical Ropivacaine Hydrochloride Injection Passed Consistency Evaluation

    • Last Update: 2021-06-04
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On June 1, Zhejiang Xianju Pharmaceutical issued an announcement stating that the company had recently received the "Drug Supplementary Application Approval Notice" (notice number: 2021B01595) on ropivacaine hydrochloride injection approved and issued by the National Medical Products Administration.


    The basic information of the drug is as follows:

    It is reported that ropivacaine hydrochloride injection is the first pure L-body long-acting amide local anesthetic.


    Ropivacaine Hydrochloride Injection was developed in 1994 by Astra Company of Sweden (the company merged with the British Zeleca Company to form AstraZeneca Pharmaceutical Co.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.